201349-37-3 Usage
Uses
Used in Pharmaceutical Industry:
1-Methyl-4-[[(phenylmethyl)amino]carbonyl]pyridinium iodide is used as an antiviral agent for the treatment of influenza. It has been approved for clinical use in 11 countries, including Ukraine, Russia, Belarus, Kazakhstan, and Uzbekistan. 1-Methyl-4-[[(phenylmethyl)amino]carbonyl]pyridinium iodide exhibits antiviral activity against influenza viruses in vitro, which supports its reported clinical efficacy against influenza virus infections.
In addition to its direct antiviral effects, Enisamium iodide may also have potential applications in other areas of medicine, such as the development of new antiviral drugs or the enhancement of existing treatments. However, further research and clinical trials would be necessary to explore these possibilities and fully understand the compound's therapeutic potential.
Check Digit Verification of cas no
The CAS Registry Mumber 201349-37-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,0,1,3,4 and 9 respectively; the second part has 2 digits, 3 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 201349-37:
(8*2)+(7*0)+(6*1)+(5*3)+(4*4)+(3*9)+(2*3)+(1*7)=93
93 % 10 = 3
So 201349-37-3 is a valid CAS Registry Number.
201349-37-3Relevant academic research and scientific papers
ALPHA-CRYSTALLINE FORM OF CARBABENZPYRIDE
-
Page/Page column 4, (2012/12/14)
The present invention relates to a new crystalline form of carbabenzpyride of formula (I) and the process for its preparation. Further, the invention relates to the use of this new crystalline form of carbabenzpyride in the treatment and prevention of vir
α-CRYSTALLINE FORM OF CARBABENZPYRIDE
-
Page/Page column 13-15, (2012/01/06)
The present invention relates to a new crystalline form of carbabenzpyride of formula (I) and the process for its preparation.
ALPHA-CRYSTALLINE FORM OF CARBABENZPYRIDE
-
Page/Page column 14-16, (2012/01/06)
The present invention relates to a new crystalline form of carbabenzpyride of formula (I) and the process for its preparation. Further, the invention relates to the use of this new crystalline form of carbabenzpyride in the treatment and prevention of vir
